Group 1 - The stock price of Haoyuan Pharmaceutical (688131) closed at 51.89 yuan on July 4, 2025, with an increase of 3.26% and a trading volume of 81,700 shares, resulting in a transaction amount of 420 million yuan [1] - On July 4, the net inflow of main funds was 20.6555 million yuan, accounting for 4.92% of the total transaction amount, while retail investors had a net outflow of 38.5298 million yuan, accounting for 9.18% [1][4] - The company announced a share repurchase and cancellation of 47,725 shares due to the failure of a performance commitment by a related party, resulting in a change in total share capital from 211,609,573 shares to 211,561,848 shares [1][4] Group 2 - The convertible bond "Haoyuan Convertible Bond" will have its conversion price adjusted from 40.58 yuan to 40.59 yuan per share, effective from July 8, 2025, following the share repurchase [2] - The bond will be suspended from conversion starting July 7, 2025, and will resume on July 8, 2025 [2][4] - The company issued 822.35 million yuan of convertible bonds with a maturity of six years, with an initial conversion price of 40.73 yuan per share [2]
股市必读:皓元医药(688131)7月4日主力资金净流入2065.55万元,占总成交额4.92%